Publications by authors named "K Foucar"
Background: Acute myeloid leukemia (AML) with RAM immunophenotype is a newly recognized high-risk AML immunophenotypic subcategory characterized by blasts with bright expression of CD56 and weak to absent expression of CD45, HLA-DR, and CD38, as first described by the Children's Oncology Group (COG). The relationship between AML-RAM and other CD56-positive acute leukemias is unclear. The goal of this study is to characterize the clinicopathological characteristics of AML with RAM phenotype and compare them with other CD56 co-expressing acute leukemias.
View Article and Find Full Text PDFBackground: Aggressive NK/T-Cell neoplasms are rare hematological malignancies characterized by the abnormal proliferation of NK or NK-like T (NK/T) cells. CD6 is a transmembrane signal transducing receptor involved in lymphocyte activation and differentiation. This study aimed to investigate the CD6 expression in these malignancies and explore the potential of targeting CD6 in these diseases.
View Article and Find Full Text PDFObjectives: The practicing pathologist is challenged by the ever-increasing diagnostic complexity of myeloid neoplasms. This guide is intended to provide a general roadmap from initial case detection, often triggered by complete blood count results with subsequent blood smear review, to final diagnosis.
Methods: The integration of hematologic, morphologic, immunophenotypic, and genetic features into routine practice is standard of care.
Article Synopsis
- Mixed phenotype acute leukemia (MPAL) is a rare type of leukemia that features cells expressing multiple lineage markers, and the WHO's revised classification excludes certain forms of this disease from being classified as MPAL.
- This study focuses on understanding the genetic characteristics and clinical outcomes of MPAL with complex karyotype (CK) in comparison to acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) with CK, revealing no significant survival differences among them.
- The findings highlight that while TP53 mutations are more common in AML with CK and worsen prognosis across all leukemia types, MPAL with CK has poor outcomes regardless of treatment regimen, reinforcing the need for its reclassification in future diagnostic criteria.